Medpace Holdings (MEDP) EBIT (2015 - 2026)

Medpace Holdings has reported EBIT for 12 years, with the latest figure at $141.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 24.65% year-over-year to $141.5 million; the trailing twelve-month figure through Mar 2026 stood at $562.9 million (up 23.36% YoY), and the FY2025 full-year result was $534.9 million, up 19.71% from the prior year.
• EBIT for Q1 2026 stood at $141.5 million, down from $153.3 million in the prior quarter.
• The five-year high for EBIT was $153.3 million in Q4 2025, with the low at $60.2 million in Q2 2022.
• Historically, EBIT has averaged $102.3 million across 5 years, with a median of $104.1 million in 2024.
• Annual changes were most pronounced in 2022 — EBIT jumped 44.89% — and 2025, when it advanced 9.08%.
• Medpace Holdings' EBIT stood at $76.4 million in 2022, then grew by 14.25% to $87.3 million in 2023, then jumped by 43.58% to $125.4 million in 2024, then increased by 22.25% to $153.3 million in 2025, then fell by 7.68% to $141.5 million in 2026.
• The last three EBIT figures came in at $141.5 million (Q1 2026), $153.3 million (Q4 2025), and $141.8 million (Q3 2025), per Business Quant data.